Panelists discuss how pivotal RVO trial data for aflibercept 8 mg show strong durability and visual outcomes while raising ...

Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more flexible treatment strategies across retinal vascular diseases.

Please provide your email address to receive an email when new articles are posted on . Continuous growth of macular neovascularization size, as well as development of outer retina atrophy, was ...

STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who previously ...

Please provide your email address to receive an email when new articles are posted on . SEATTLE — In this Healio Video Perspective from the ARVO meeting, Jennifer I. Lim, MD, discusses anti-VEGF ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...

Researchers led by a team at the Wilmer Eye Institute, Johns Hopkins Medicine, have discovered why vision in some patients with neovascular (nv) or “wet” age-related macular degeneration (nvAMD, or ...

Early response to treatment with anti–vascular endothelial growth factor (VEGF) agents may predict long-term outcomes among patients with diabetic macular edema (DME), a small study suggests. "Our ...

Patients assigned to SRT received an average of 10.7 doses of ranibizumab (Lucentis) over 2 years as compared with 13.3 for patients assigned to sham SRT. Best-corrected visual acuity (BCVA) did not ...